Expert second opinions for cardiac tumors. Dual-physician Heart Team review with triple risk scoring. Results in 24 hours.
Cardiac Tumors are rare, with primary tumors occurring in less than 0.1% of the population. If you are facing a decision about cardiac tumors, an independent Heart Team second opinion can confirm whether surgery is the right choice and identify alternatives. WhiteGloveMD delivers dual-physician review with STS, EuroSCORE II, and AATS risk scoring in 24 hours. Get an independent second opinion →
Cardiac tumors are rare, with primary tumors occurring in less than 0.1% of the population. The most common benign tumor is atrial myxoma, while papillary fibroelastoma is the most common valvular tumor. Primary malignant tumors (sarcomas) and metastatic disease also occur.
The rarity of cardiac tumors means most physicians encounter few cases in their career. Distinguishing tumor types, determining surgical necessity and approach, and managing rare malignant tumors all benefit from specialized expertise. Some tumors (fibroelastomas) can be observed, while others (myxomas) require urgent removal.
Surgery for cardiac tumors depends on symptom severity, imaging findings, and risk profile. Guidelines from the AHA/ACC define specific thresholds, but many patients fall into gray zones where a second opinion meaningfully changes the recommendation. The rarity of cardiac tumors means most physicians encounter few cases in their career. Distinguishing tumor types, determining surgical necessity and approach, and managing rare malignant tumors all benefit from specialized expertise. Some tumors (fibroelastomas) can be observed, while others (myxomas) require urgent removal.
Operative mortality for cardiac tumors-related cardiac surgery is calculated using validated models including STS PROM, EuroSCORE II, and AATS. Individual risk depends on age, comorbidities, frailty, ejection fraction, and surgeon/center volume. Our free calculator at whiteglovemd.com/tools/risk-calculator estimates your specific risk across all three models in real time.
Yes. Studies show that 30-40% of expert cardiac surgery second opinions change the original treatment plan — sometimes by recommending less-invasive alternatives, sometimes by clarifying that watchful waiting is safer. WhiteGloveMD pairs a cardiac surgeon and cardiologist with our Clintelligence multi-agent AI pipeline to deliver an independent review in 24 hours, starting at $500.
The optimal treatment for cardiac tumors depends on anatomy, comorbidities, age, and personal goals. Surgical necessity vs observation. A Heart Team review evaluates every viable option — including transcatheter approaches, repair vs replacement, and surgeon/center matching — rather than defaulting to a single recommendation.
WhiteGloveMD delivers a dual-physician, AI-augmented second opinion in 24 hours. Starting at $500.